AML5 blasts, but different cytokines are involved in CD44-induced differentiation of AML5 blasts (IL-8 and GM-CSF) and THP-1 cells . This suggests that distinct AML5 cases are responsive to distinct cytokines. For this reason, we believe that the noteworthy ability of CD44 to activate a wide range of autocrine cytokine synthesis, explains, at least in part, why CD44-targeting is so successful in inducing differentiation of AML5 blasts.
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML (a) Cells were treated with 50 mg/ml of H3 anti-CD44 mAb or IgG (controls), in the presence or not of the ERK1/2 inhibitor U0126 (10 mM). At the indicated times, cells were harvested and RNA was extracted. Complementary DNA were synthesized and subjected to quantitative real-time reverse transcriptase polymerase chain reaction (Q-RT-PCR) to measure IL-6 and TNF-a mRNA levels, as previously described. 2 The bars show the fold-increase in mRNA levels in H3-treated compared with IgG-treated control cells. Data are mean ± 1 s.d., representative of three independent experiments. (b) Cells were treated for indicated times with H3 anti-CD44 mAb, in absence or presence of U0126, or with IgG (controls). The amount of TNF-a and IL-6 in culture media was measured by specific ELISA assay. Data (pg/ml) are mean ± 1 s.d., representative of three independent experiments.
Letters to the Editor as well as an adjacent hydrophobic binding site accessible solely when the kinase is in an inactivated configuration and (3) non-ATP competitive inhibitors that bind at sites outside the ATP-binding site that affect kinase activity.
1 Second-generation Abl inhibitors in clinical use for chronic myeloid leukemia, such as the type I inhibitor, dasatinib, and the type II inhibitor, nilotinib, show significantly more potency against BCR-ABL than imatinib, and inhibit most imatinib-resistant BCR-ABL mutants with the exception of the T315I 'gatekeeper' mutant. [2] [3] [4] [5] HG-7-85-01 represents a new class of type II ATP-competitive inhibitors capable of inhibiting T315I-BCR-ABL, as well as gatekeeper mutants of Kit (T670I-KIT) and PDGFRa (T674I/MPDGFRa) that are clinically observed in gastrointestinal stromal tumor and hypereosinophilic syndrome. 6 HG-7-85-01 is distinctive in having the ability to accommodate either a gatekeeper threonine, present in the nonmutated forms of target kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. . Vehicles (n ¼ 6). Treatment mice were administered 1 Â daily 50 mg/kg GNF-5 (n ¼ 5), 1 Â daily 100 mg/kg HG-7-85-01 (n ¼ 6) or 1 Â daily a combination of GNF-5 and HG-7-85-01 at the aforementioned doses (n ¼ 4). Baseline imaging was performed 2 days after i.v. injection of 32D.p210-luc þ cells. Mice were treated for a total of four consecutive days, before imaging on day 6 after i.v. (with no drug treatments for that day), and followed by two additional days of drug treatment with imaging on day 9 after i.v. Three mice (32D.p210-luc þ cell-injected) died between day 6 and day 9 after i.v. injection of cells (B550-combination (found dead on day 9 after i.v. day of imaging), B546-GNF-5 only (died on day 8 after i.v. day of imaging) and D532-combination (died on day 8 after i.v. day of imaging) (P ¼ 0.0002, one-way analysis of variance)). The difference in tumor burden between vehicle-treated mice and GNF-5-only treated mice was less significant (P ¼ 0.006) than the difference in tumor burden between vehicle-treated mice and combination-treated mice (P ¼ 0.002). 
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The GNF-2 and GNF-5 family of inhibitors bind to the myristate binding site of BCR-ABL and inhibit kinase activity by stabilizing a catalytically less competent conformation of the kinase.
7,8 GNF-5 exhibits additive inhibitory activity with nilotinib in cellular and in vivo models against both nonmutated and T315I-BCR-ABL. 8 The combination of more than one Abl inhibitor in the treatment of imatinib-resistant disease may have beneficial therapeutic value, because clonal resistance could potentially be overcome by combining two agents with different resistance profiles. We investigated the ability of HG-7-85-01, which inhibits T315I, 6 to positively combine with the allosteric non-ATP competitive inhibitor, GNF-5, which is unable to potently inhibit T315I as a single agent. 8 We show here that combinations of HG-7-85-01 with GNF-5 have at least additive effects against both nonmutated BCR-ABL and T315I-BCR-ABL in vitro and in vivo.
HG-7-85-01 was observed to positively combine with GNF-5 in vitro against Ba/F3.p210 cells (CalcuSyn combination indices: ED25, 0.15 (strong synergism); ED50, 0.25 (strong synergism); ED75, 0.40 (synergism); ED90, 0.65 (synergism)). The two inhibitors were also shown to positively combine in vivo against 32D.p210-luc þ xenografted cells (Figure 1) .
The combination of HG-7-85-01 and GNF-5, as compared to either agent alone, effectively killed more T315I-positive cells in vitro (Figure 2) . In vivo combination studies were also performed, investigating the effects of HG-7-85-01 and GNF-5 as compared to each agent alone. The average percent spleen size in HG-7-85-01 þ GNF-5-treated mice harboring T315I-positive leukemia was smaller than mice treated with either single agent or mice treated with vehicle ( Figure 3 ).
In conclusion, the non-ATP competitive inhibitor, GNF-5, was observed to positively combine with the type II inhibitor, HG-7-85-01, and the type II inhibitor, nilotinib, respectively, against BCR-ABL in vitro and in a bioluminescent mouse model of BCR-ABL-positive leukemia. Similarly, the combination of GNF-5 and HG-7-85-01 was observed to inhibit T315I-BCR-ABL-positive leukemia cell growth in vitro to a greater extent than either drug alone. Tumor burden in mice harboring 32D.p210-T315I-luc þ cells treated with a combination of HG-7-85-01 and GNF-5 was suppressed to a higher extent than mice treated with vehicle or either agent alone. The ability of two such structurally distinct, targeted Abl inhibitors to positively combine introduces a novel approach to overriding imatinib-resistant leukemia, including that caused by the highly prevalent and strongly imatinib-resistant gatekeeper mutant, T315I.
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JDG, NG and ALK have a financial interest with Novartis Pharma AG. Figure 3 In vivo combination studies between HG-7-85-01 and GNF-5 against T315I-BCR-ABL. Day 9 after i.v. injection of 1 000 000 32D-T315I-luc þ cells per mouse. (a) Percent spleen weights are shown for vehicles (n ¼ 7) and treatment mice, the latter administered 1 Â daily 100 mg/kg GNF-5 (n ¼ 6), 1 Â daily 100 mg/kg HG-7-85-01 (n ¼ 5) or 1 Â daily a combination of GNF-5 and HG-7-85-01 at the aforementioned doses (n ¼ 4). Baseline imaging was performed 2 days after i.v. injection of 32D.p210-luc þ cells. Mice were treated for a total of four consecutive days, with 1 day of no drug treatment, and followed by two additional days of drug treatment with imaging on day 9 after i.v. Three mice that were initially injected with 32D-T315I-luc þ died during the course of the study prematurely and were not included in the final spleen weight analysis (I507-HG-7-85-01 (found dead on day 6 after i.v.), I508-combination (found dead on day 6 after i.v.) and J523-combination (died on day 7 after i.v.)). There was a statistically significant difference between percent spleen size observed in combination-treated mice and vehicle-treated mice (P ¼ 0.046). This study is representative of three independent studies in which similar results were observed. HG-7-85-01 is the same as the label 'HG85' that is shown in the graph. (b) Spleens dissected from mice tested in this study.
Systemic mastocytosis (SM) is a stem-cell-derived clonal myeloproliferation characterized by an accumulation of abnormal mast cells. A majority of SM patients harbor the KITD816V mutation, indicating its potentially important role in disease pathogenesis. KITD816V activates several downstream signaling pathways including PI3-kinase/AKT, STAT5 and ERK-1/2 that mediate its proliferative, survival and differentiation effects. SRC family kinases have an important role in stem cell factor (SCF)-induced cell proliferation; in SCF-responsive cell lines and hematopoietic progenitor cells, LYN is associated with the juxtamembrane region of KIT, and is rapidly phosphorylated in response to SCF stimulation. 1 Coexpression of KIT with functionally defective CBL, normally a negative regulator of KIT, in murine bone marrow cells leads to generalized mastocytosis. 2 Interestingly, KIT kinase activity was dispensable for cell transformation mediated by mutant CBL; instead, transformation was dependent on the SRC family kinase, FYN. Furthermore, recent data suggest that SRC kinase activity is important for full expression of KITD816V's transforming potential; KITD816V not only activates receptor kinase activity, but also subverts its substrate specificity to confer SRC-like 
